Gemcitabine/Cisplatin
Phase 3Small molecule
AstraZenecaGemcitabine/Cisplatin is one of 108 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 3.
3
Indications
16
Total Trials
6
Active Trials
107
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Ensacove
XXcovery Holdings, Inc.
Phase 3
Tiragolumab
RochePhase 3
Gemcitabine/Cisplatin
AstraZenecaPhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Biliary Tract Cancer4 trials
Breast Cancer3 trials
Nasopharyngeal Carcinoma2 trials
2 more indications
Non-small Cell Lung Cancer (NSCLC)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Gemcitabine/Cisplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company